Revelation Biosciences

Historical price data

Revelation Biosciences is developing GEMINI, a first-in-class innate immune system modulator designed to rebalance inflammation and prevent tissue damage. The company has generated positive early clinical data in preventing Acute Kidney Injury (AKI) and is exploring its platform's potential in broad inflammatory and infectious conditions. Its strategy hinges on clinically validating its 'innate immune conditioning' hypothesis in surgical settings as a pathway to addressing larger, dysregulated inflammatory markets. As a pre-revenue, NASDAQ-listed entity, its near-term value catalysts are tied to clinical trial readouts and strategic partnership development.

Proprietary innate immune conditioning platform using a synthetic TLR4 agonist (PHAD®) to reprogram the immune system to respond to stress in an attenuated manner, aiming to reduce inflammatory tissue damage.

Faces limited direct competition in AKI prevention but operates in the crowded, high-failure-rate field of acute immunomodulation. Must differentiate from broad immunosuppressants and failed cytokine-targeting agents by proving its conditioning approach offers a superior efficacy/safety profile.